- 274686-05-4Cyclohexanecarboxylic acid,1-[(8-quinolinylsulfonyl)amino]-
- 274692-08-91-Pyrrolidinecarboxylicacid, 3-(2-aminoethyl)-, 1,1-dimethylethyl ester, (3S)-
- 274693-27-5Ticagrelor
- 274693-53-7Carbamicacid,N-[(3aS,4R,6S,6aR)-tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]-,phenylmethyl ester
- 274693-55-9Ticagrelor Intermediate1
- 27469-53-01,3,5-Triazine-2,4-diamine,6-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-N2,N4-di-2-propen-1-yl-
- 27469-60-9Piperazine,1-[bis(4-fluorophenyl)methyl]-
- 27469-61-0Piperazine,1-[bis(4-chlorophenyl)methyl]-
- 27470-51-5Butanedioic acid,1-[(4-butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl] ester
- 2747-05-92H-1-Benzopyran-2-one,7-(acetyloxy)-4-methyl-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Prolixin enanthate |
EINECS | N/A |
| CAS No. | 2746-81-8 | Density | 1.181g/cm3 |
| PSA | 61.32000 | LogP | 6.77020 |
| Solubility | N/A | Melting Point |
184.5°C |
| Formula | C29H38 F3 N3 O2 S | Boiling Point | 629.4°Cat760mmHg |
| Molecular Weight | 549.701 | Flash Point | 334.4°C |
| Transport Information | N/A | Appearance | N/A |
| Safety | Poison by intravenous, intramuscular, intraperitoneal, and subcutaneous routes. Human systemic effects by subcutaneous route: muscle weakness; by intramuscular route: musculo-skeletal changes. When heated to decomposition it emits very toxic fumes of F−, SOx, and NOx. | Risk Codes | N/A |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
Heptanoicacid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester (7CI,8CI); 1-Piperazineethanol,4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-, heptanoate (ester) (8CI);4-[3-(2-Trifluoromethyl-10-phenothiazinyl)propyl]-1-piperazineethanolenanthate; Fluphenazine enanthate; Moditen enanthate; Prolixin enanthate; SQ16,114; SQ 16144 |
Prolixin enanthate Chemical Properties
IUPAC Name: 2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl heptanoate
Synonyms of Prolixin enanthate (CAS NO.2746-81-8): 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl heptanoate ; 4-(3-(2-Trifluoromethyl-10-phenothiazinyl)propyl)-1-piperazineethanol enanthate ; Eutimox ; Fluphenazine enantate ; Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
CAS NO: 2746-81-8
Molecular Formula: C29H38F3N3O2S
Molecular Weight : 549.6911
Molecular Structure: .png)
EINECS: 220-385-0
H bond acceptors: 5
H bond donors: 0
Freely Rotating Bonds: 13
Polar Surface Area: 61.32 Å2
Index of Refraction: 1.544
Molar Refractivity: 146.97 cm3
Molar Volume: 465.4 cm3
Surface Tension: 40.6 dyne/cm
Density: 1.181 g/cm3
Flash Point: 334.4 °C
Enthalpy of Vaporization: 93.11 kJ/mol
Boiling Point: 629.4 °C at 760 mmHg
Vapour Pressure: 9.41E-16 mmHg at 25°C
Prolixin enanthate Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| human | TDLo | intramuscular | 1633ug/kg (1.633mg/kg) | MUSCULOSKELETAL: OTHER CHANGES | British Medical Journal. Vol. 2, Pg. 1071, 1966. |
| human | TDLo | subcutaneous | 357ug/kg (0.357mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS | American Journal of Psychiatry. Vol. 119, Pg. 779, 1963. |
| mouse | LD50 | intramuscular | 17200ug/kg (17.2mg/kg) | Drugs in Japan Vol. 6, Pg. 701, 1982. | |
| mouse | LD50 | intraperitoneal | 300mg/kg (300mg/kg) | Drugs in Japan Vol. 6, Pg. 701, 1982. | |
| mouse | LD50 | intravenous | 56mg/kg (56mg/kg) | U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#03337, | |
| mouse | LD50 | oral | 41300ug/kg (41.3mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969. | |
| mouse | LD50 | subcutaneous | 50mg/kg (50mg/kg) | Drugs in Japan Vol. 6, Pg. 701, 1982. | |
| rat | LD50 | intraperitoneal | 230mg/kg (230mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969. | |
| rat | LD50 | oral | 230mg/kg (230mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969. | |
| rat | LD50 | subcutaneous | 475mg/kg (475mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969. | |
| women | TDLo | intramuscular | 250ug/kg (0.25mg/kg) | BRAIN AND COVERINGS: CHANGES IN SURFACE EEG BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: COMA | Italian Journal of Neurological Sciences. Vol. 1, Pg. 193, 1980. |
Prolixin enanthate Safety Profile
Poison by intravenous, intramuscular, intraperitoneal, and subcutaneous routes. Human systemic effects by subcutaneous route: muscle weakness; by intramuscular route: musculo-skeletal changes. When Prolixin enanthate (CAS NO.2746-81-8) is heated to decomposition, it emits very toxic fumes of F−, SOx, and NOx.
RIDADR: 3249
HazardClass: 6.1(b)
PackingGroup: III
What can I do for you?
Get Best Price
